Scholarlink

A new era in the treatment of disorders of bone began about 45 years ago with the introduction of bisphosphonates (BP) into clinical practice. BP are deposited on the surface of the bones, inhibiting osteoclasts and thus resorption of bone. Consequently, these drugs have long been given to patients with Morbus Paget, with hypercalcaemia, with multiple myeloma and with osseous metastases. BP not only inhibit resorption of bone, but they also inhibit the growth of metastases in bone and marrow.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bisphosphonates

  • 章节

  • 发表日期：

    2026年

查看全文
  • Reiner Bartl,
  • Christoph Bartl

摘要

A new era in the treatment of disorders of bone began about 45 years ago with the introduction of bisphosphonates (BP) into clinical practice. BP are deposited on the surface of the bones, inhibiting osteoclasts and thus resorption of bone. Consequently, these drugs have long been given to patients with Morbus Paget, with hypercalcaemia, with multiple myeloma and with osseous metastases. BP not only inhibit resorption of bone, but they also inhibit the growth of metastases in bone and marrow.